Project

Back to overview

Cell therapy of congestive heart failure using in vitro-generated cardiomyocytes

Applicant Jaconi Marisa
Number 58712
Funding scheme NRP 46 Implants and Transplants
Research institution Département de Pathologie et Immunologie Faculté de Médecine / CMU Université de Genève
Institution of higher education University of Geneva - GE
Main discipline Biology and Medicine
Start/End 01.01.2001 - 30.06.2006
Approved amount 552'109.00
Show all

Lay Summary (English)

Lead
Lay summary
Cell Therapy of Congestive Heart Failure Using In vitro-generated Cardiomyocytes

Background/Problem
Chronic congestive heart failure (CHF) represent a major cause of cardiovascular morbidity and mortality in developed countries. Besides heart transplantation, no causal therapy is available.

Objective
As the use of human embryonic stem cells is ethically problematic, we will use an embvrxonic stem cell clone from mouse origin. In general, in vitro ESC are characterized by their ability to differentiate spontaneously into various cell lines, amongst them CCCs. Stable transfection of ESC with green fluorescent protein under the control of a cardiac-specific promoter will allow easy identiication of CCCs as well as their rapid purification by fluoresent cell sorting.

Approach
Consequently, in vitro obtained CCC, will bed delivered to the myocardium of mice by either direct intramyocasrdial injection or indirectly via application into laser-generated transmyocardial channels. In initial eperiments, mouse-derived CCCs will be delivered to healthy isogenic mice in order to test cell aurvival and integration of implanted cells in the caardiac tissue. Once this technology is optimized, subsequent experiments will finally consist in the engraftmnt of CCCs into transgenic animals with CHF. Short a long-term effects of cell therapy in, first, healthy and, utimately, in animals with CHF will bechaacterized by measuring hemodynamic, cardiac and motphologic parameters.

In the future, cell therapy might help to treat CHF effectively, avoiding either long-standing and costly drug treatment or to treat patients on a waiting list for a transplant. Of importace for the clinical impact of the proposed project is its nature as platform for collaboraion between a cell biologist, a geriatric physician, a heart surgeon and a pahologist. The important participation of clinicians in this project will ensure rapid transfer of positive results into clinical studies. <
Direct link to Lay Summary Last update: 21.02.2013

Responsible applicant and co-applicants

Employees

-